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a  b  s  t  r  a  c  t
The  purpose  of  the  present  study  was  to design  nanoassemblies  of chitosan-titanium  dioxide  (TiO2)
nanoparticles  (NPs)  loaded  with  glucantime  for using their  synergistic  effects  and  enhancing  the toxic
effects  of  glucantime  on  Leishmania  parasites.  The  nanoassemblies  were  prepared  by  electrostatic  inter-
actions  and  optimized  by  a response  surface  central  composite  design.  The  effects  of  glucantime,  chitosan
and  TiO2 NPs  amounts  were  studied  on the  particle  size,  zeta  potential,  loading  efﬁciency,  and  release
efﬁciency  of  drug  from  nanoassemblies.  The  conjugation  of TiO2/chitosan-glucantime  was  veriﬁed  by UV
spectroscopy  and  changes  in  surface  charge  of  NPs.  The  anti-promastigots  effect  of glucantime  loaded
in  TiO2/chitosan  nanoassemblies  was  studied  by  tripan  blue  dye  test  and  their  anti-amastigotes  effect
by  counting  the  average  number  of  parasites  per  infected  J774  macrophages  in 100  cells.  The  optimizedromastigote
mastigote
eishmania major
formulation  obtained  by using  12.5 mg  glucantime,  25  mg  chitosan  and  6 mg  TiO2 NPs. Although  TiO2
NPs  alone  were  effective  more  than  negative  control  in  reduction  of  promastigots  and  amastigotes  but
they  didn’t  show  signiﬁcant  difference  compared  with  free  glucantime  (p >  0.05).  However,  at  the  con-
centration  of  50  g/mL  and  after 72 h exposure  nanoassemblies  decreased  the  proliferation  of  L.  major
promastigotes  and  amastigotes  13  and  4-fold,  respectively  compared  with  glucantime  alone.
©  2017  Elsevier  B.V.  All  rights  reserved.. Introduction
Metal nanoparticles (NPs) have cytotoxic effects on the different
icroorganisms due to their small size and their structures that dis-
upt DNA functions and enzymes and release of ions [1], however,
he mechanism of their actions is not well known yet [2]. These NPs
ct by producing reactive oxygen intermediates that damage cell
embrane structures [3].
Titanium dioxide (TiO2) NPs are used widely in industrial and
iological products [4,5]. These NPs are classiﬁed as biological
armless and inert materials that are used in many functions. TiO2
s an FDA approved excipient in drug and food industries and is an
ngredient of several oral pharmaceutical dosage forms like tablets
∗ Corresponding author at: Department of Pharmaceutics, Faculty of Pharmacy
nd Novel Drug Delivery Systems Research Centre, Isfahan University of Medical
ciences, Isfahan, PO Box 81745-359, Iran
E-mail address: varshosaz@pharm.mui.ac.ir (J. Varshosaz).
ttps://doi.org/10.1016/j.ijbiomac.2017.08.177
141-8130/© 2017 Elsevier B.V. All rights reserved.or suspensions [6]. TiO2 NPs have demonstrated widely antibacte-
rial effects due to their activity on oxidative stresses [7]. Producing
reactive oxygen species (ROS) by macrophages are taking place in
order to destroy virus, fungi and parasites. Leishmania parasites
survive in macrophages by inhibition of ROS productions via their
enzymatic pathway. Metal NPs can overcome this reaction of Leish-
mania parasites and contribute in treatment successes [2]. TiO2 NPs
have strong antibacterial effects against drug resistant bacteria and
have cytotoxic effects on Leishmania parasites. NPs of Ag/TiO2 have
anti Leishmanial effect against L. tropica and L. infantum [5]. These
particles inhibit survival, metabolism and biological activities of
Leishmania in host cells. Research of Haghi et al. [8] indicated TiO2
NPs have antibacterial effects on E. coli. The investigations of Jebali
and Kazemi [2] showed TiO2 with IR and UV radiation together
increase mortality of parasites. However, there is no article that
mention the role of TiO2 nanoassembly with a biological macro-
molecule like chitosan in drug delivery. TiO2 has been used in
targeted drug delivery of paclitaxel [9] and doxorubicin for enhanc-
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ng the anticancer efﬁcacy and reducing unwanted side effects of
hese chemotherapeutic drugs [10].
Leishmania is a major global health problem and widespread
n 100 countries of the world so that one million new cases are
eported each year [11–14]. Pentavalent antimonial (SbV) com-
ounds such as meglumine antimoniate (MA) are still the ﬁrst line
reatment and the choice medicine against Leishmaniasis.  Glucan-
ime (N-methyl glucamine antimoniate) with molecular weight of
65.98 g/mol is a penta valent antimoniate that is highly soluble
n water (solubility >300 mg/mL) [15]. In this compound one anti-
ony is associated with N-methyl-d-glucosamine molecules and it
s thought that acts as a prodrug that is transformed to toxic form of
rivalent form (SbШ) in macrophages [16]. For treatment of cuta-
eous and visceral Leishmaniasis 10–20 mg/kg/day of this drug is
sed for 20–30 days [17,18] in the form of 1500 mg/5 mL  injection.
Despite several years of use of these compounds, their mecha-
ism of action, structure, toxicity, pharmacokinetics and ability to
amage DNA are still unclear [16,19]. The latest study in this regard
as conducted based on radio tracer by neutron irradiation on
nimals to determine pharmaceutical aspects of these compounds
hich showed that antimony serum kinetic was bi-exponential, the
rug was uptake from liver and eliminated through biliary excre-
ion and kidneys [20].
Antimony compounds have a long duration of treatment course
n hospital and have shown clinical resistance especially in HIV
atients. They have many side effects including vomiting, arthral-
ia, and toxic side effects on vital organs such as liver, kidney, heart
nd pancreas [21]. Due to all these reasons long-term monitoring
s required during drug use which makes costs of treatment high.
lso drug injection for a prolonged period of 10–20 days leads to
oor compliance.
Many studies have been done using nanoparticlulate deliv-
ry systems for antileishmania drugs. In a study the effects of
entamidine bound to polymethacrylate was investigated against
eishmania in vivo [22,23]. The results showed that 77% of
mastigote reduction happened in the treatment group compared
ith control group. Also several studies have been conducted
egarding the effectiveness of Iridium-cyclo-octadiene pentami-
ine tetraphenyl borate on various species of Leishmania [24,25].
Abamor et al. [26] used the combination of TiO2, Ag Nps and
eglumine antimoniate which showed to be much more effective
han use of meglumine antimoniate alone at non-toxic concentra-
ions as a new antileishmanial drug to ﬁght against Leishmaniasis.
According to available reports on the toxic effects of TiO2 NPs
n Leishmania parasites, in the present study it was trying to use a
ovel macromolecular nanoassembly drug delivery system based
n chitosan and without Ag NPs to gain a synergistic effect between
iO2 and glucantime on promastigote and amastigote forms of
eishmania major by using an electrostatic conjugation technique.
o our knowledge there is no report on the production of chitosan
anoparticles loaded with glucantime which are electrostatically
onjugated to TiO2 to use of their synergistic effects in suppression
f both promastigote and amastigote forms of Leishmania major in
 sustained release pattern.
. Material and methods
.1. Materials
Meglumine antimoniate (Glucantime) was provided from Snoﬁ
ventis (French), low molecular weight chitosan from Sigma Com-
any (US), titanium dioxide nanoparticles from Nanosav Avijeh
Iran), glacial acetic acid and all other reagents were purchased
rom Merck Chemical Company (Germany). Roswell Park Memo-
ial Institute 1640 medium (RPMI-1640), Novy-MacNeal-Nicolleical Macromolecules 107 (2018) 212–221 213
medium (NNN), fetal bovine serum (FBS), trypsin/EDTA, peni-
cillin/streptomycin were obtained from (Biosera Europe, ZI du
Bousquet, France).
2.2. Preparation of nanoassemblies of TiO2 NPs and glucantime
Nanoassemblies were obtained via an electrostatic conjugation
method. Brieﬂy, pure powder of meglumine antimoniate (glucan-
time) was  dissolved in 50 mL  of deionized water and added to the
solution of chitosan in 0.2% of glacial acetic acid to make a total
volume of 100 mL.  The mixture was  stirred at room temperature
for 2 h until completely dissolved. The dispersion of TiO2 NPs was
diluted as a 1% stock solution in 20 mL  of deionized water. After
that while the solution of drug-chitosan was stirred under ultra-
homogenizer (RT10 power IKa
®
- werke, Germany) at 17,500 rpm,
the dispersion of TiO2 was  added drop by drop via a syringe until a
yellow transparent dispersion of nanoassemblies was obtained at
the end. In order to further reduce the particle size, probe sonica-
tion (Bandelin Sonopuls, Germany) was  used for 2 min  with power
of 50%.
Different formulations were designed by Design Expert Soft-
ware (10.0.4 version, US) using a surface response central
composite design with quadratic model, and the optimum formu-
lation was  obtained. The amounts of glucantime, chitosan and TiO2
were changed according to Table 1.
Graphical representation of the prepared nanoassemblies of
TiO2 NPs and glucantime are shown in Fig. 1.
2.3. Characterization of the nanoassemblies of
glucantime-chitosan-TiO2 NPs
2.3.1. Particle size and zeta potential
The particle size, particle size distribution and zeta potential
of the prepared nanoparticles were determined by using Zetasizer
(Zetasizer-ZEN 3600 Malvern Instrument Ltd., Worcestershire, UK)
that works based on dynamic light scattering technique.
2.3.2. Ultra violet analysis of the ingredients
UV spectrum of glucantime, chitosan, glucantime-chitosan, tita-
nium dioxide and prepared nanoassemblies were analyzed in the
range of 220–600 nm using a Shimadzue UV-mini1240 spectropho-
tometer (Japan).
2.3.3. Determination of glucantime content of nanoassemblies
Drug loading efﬁciency (LE%) was measured by determination
of the concentration of free drug in aqueous medium. For this
purpose 1 mL  of the prepared nanoassemblies was centrifuged at
20,000 rpm for 10 min  in micro-centrifuging ﬁlter tubes. Amount of
antimony was  measured by ICP-OES (Inductively Coupled Plasma-
Optical Emission Spectrometry) at wavelength of 217.582 nm.  The
entrapped drug was calculated from the difference between the
drug concentration in the ﬁltrated solution (free drug) and the total
amount of the applied drug.
Loading efficiency% = Total drug − free drug
Total drug
× 100 (1)
2.3.4. In vitro release of glucantime from nanoassemblies
After dialyzing of 2 mL  of the nanoassemblies dispersion in dial-
ysis bag with cutoff 12000 Da for an hour against deionized water,
the dialysis bag was transferred from water to 20 mL of phosphate
buffer solution (PBS) (pH 7.4) and sampling was conducted over
24 h at predetermined intervals. One mL  of the medium was taken
and the antimony concentration was  determined by ICP-OES spec-
trometry at wavelength of 217.582 nm. The same volume of fresh
214 J. Varshosaz et al. / International Journal of Biological Macromolecules 107 (2018) 212–221
Table 1
Formulation of different nanoassemblies of TiO2 NPs and glucantime.
Formulation code Glucantime (G) (mg) Chitosan (C) (mg) TiO2 NPs (T) (mg)
G18.75C37.5T4.65 18.75 37.5 4.65
G12.5C25T6 12.5 25 6
G18.75C19.82T9.25 18.75 19.82 9.25
G12.5C50T12.5 12.5 50 12.5
G18.75C37.5T9.25 18.75 37.5 9.25
G25C50T6 25 50 6
G18.75C37.5T13.85 18.75 37.5 13.85
G27.59C37.5T9.25 27.59 37.5 9.25
G18.75C55.18T9.25 18.75 55.18 9.25
G25C25T12.5 25 25 12.5
G9.91C37.5T9.25 9.91 37.5 9.25
blies o
b
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T
w
t
eFig. 1. Graphical representation of the nanoassem
uffer was returned to the medium. The antimony release efﬁciency
ver 24 h (RE24%) was determined by the following equation:
E24%
∫ t
0
y.dt
y100 × t
× 100 (2)
.3.5. Study the particles morphology
The morphology of chitosan-glucantime NPs was studied by
ransmission Electron Microscopy (TEM) (Zeiss, EM10C, Germany).
o prepare the TEM sample, an appropriate amount of suspension
as placed onto a 300 mesh carbon coated copper grid and allowed
o dry in air naturally. Finally, micrographs were taken with differ-
nt levels of magniﬁcation with an accelerating voltage of 80 kV.f glucantime-chitosan-titanium dioxide structure.
The morphology of the nanoassemblies of TiO2 NPs conjugated
to chitosan-glucantime were studied by Field Emission Scanning
Electron Microscope (FESEM) FESEM (Hitachi, Japan). The samples
were prepared by placing a droplet of nanoassemblies dispersion
on the microscopy slide and allowing it to dry at room temperature.
Before viewing under vacuum conditions, the samples were coated
by gold in an argon atmosphere and then tightened on the metal
plate with two  layers of adhesive tape of copper.2.4. Leishmania parasite culture
L. major (MRHO/IR/75/ER) promastigotes were cultured ﬁrst in
NNN and then RPMI1640 to reach the mass. RPMI-1640 medium
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as supplemented with 10% fetal bovine serum (FBS) (Sigma
hemical Co, US), gentamicin (80 g/mL), penicillin (100 IU/mL)
nd streptomycin (100 g/mL) at 25 ± 1◦ C. The cultures were pas-
aged after 4 days incubation and the growth of promastigotes was
onitored daily.
.5. Anti-promastigote assay
In order to assess inhibitory concentration of nanoassemblies on
. major,  96 well plates were used. Each well contained 100 L of
he medium, antibiotics and 1 × 106 parasites in stationary phase.
hen parasites were treated in different groups: 1) nanoassemblies
166.50, 83.25, 41.62 g/mL) containing the same concentrations
f pure glucantime used in the third group, 2) only TiO2 NPs
33.72, 16.86, 8.43 g/mL), 3) only glucantime (50, 25, 12.5 g/mL)
s positive control and 4) no treatment as the negative control.
he concentrations of TiO2 NPs were selected according to the
mounts of this substance present in different concentrations of
anoassemblies. Each test was repeated in triplicate and the wells
ere incubated at 24 ◦C and were evaluated after 24, 48 and 72 h.
hen the promastigotes were counted using 0.4% tripan blue dye
n a Neubauer haemocytometer counting chamber.
.6. J774 macrophage cell culture
J774 mouse macrophage cell-line was grown in a 37 ◦C culture
asks with RPMI-1640 supplemented with 10% fetal bovine serum
FBS), penicillin (100IU/mL) and streptomycin (100 g/mL). Cells
ere passaged when they reached 70% conﬂuence.
.7. Anti-amastigotes assay
J774 macrophage cells (2 × 106 cells/mL) were seeded in 6 well
lates. At the bottom of every well a sterile coverslip was  located.
he plates were incubated at 37 ◦C for 24 h. Macrophage cells were
hen infected with L. major promastigotes at a parasite/macrophage
atio of 7:1 and incubated at 37 ◦C in 5% CO2 for 24 h. Free pro-
astigotes were washed out of wells with PBS and different
oncentrations of 1) nanoassemblies (166.50, 83.25, 41.62 g/mL)
hich contained the same concentrations similar to free glucan-
ime concentrations, 2) only TiO2 (33.72, 16.86, 8.43 g/mL) and
) only free glucantime (50, 25, 12.5 g/mL) based on the Ed50
btained in preliminary studies, were added to the containers. The
ourth group received no treatment as the negative control. At three
ifferent time intervals (24, 48 and 72 h) the results were viewed
nd the coverslips were ﬁxed with methanol, stained with 10%
iemsa and added oil-immersion light microscopy for examining.
he number of infected macrophages and the average number of
arasites per macrophage were counted in 100 cells.
.8. Statistical analysis
Values were processed by Microsoft Excel 2017 and IBM SPSS
tatistics (Ver. 18, US) for determination of signiﬁcant difference
etween variables. Analysis of variance test (ANOVA) followed by
he post hoc test of LSD was done and the level of signiﬁcance was
et at P values < 0.05.
. Results
.1. Particle size and zeta potentialThe particle size distribution of nanoassemblies of TiO2 NPs and
hitosan-glucantime were determined by a dynamic light scatter-
ng (DLS) instrument. The results showed the mean particle size ofical Macromolecules 107 (2018) 212–221 215
170 nm with a polydispersity index (PDI) of 0.4 in optimum formu-
lation (G12.5C25T6) which shows low diversity of particle size. The
surface charge is an important physicochemical feature of NPs that
is determined by changing zeta potential. The zeta potential of chi-
tosan was +70 mV  and when glucantime was  added to it, it changed
to +61 mV  that shows glucantime with negative charge was con-
veniently cross-linked the chitosan with opposite charge. Finally
when TiO2 NPs were added to chitosan-glucantime NPs, the zeta
potential changed to +48 mV.  Zeta potential of TiO2 NPs alone was
−59.4 mV which indicates that they can be assembled and make
complex with positive charge of chitosan-glucantime NPs. The
results of changing the zeta potential clearly show the production
of nanoassemblies by electrostatic forces. Besides the UV spectrum
of nanoassembelies was studied to conﬁrm the electrostatic con-
jugation of chitosan-glucantime with TiO2 NPs. UV–vis spectra of
glucantime, chitosan, glucantime-chitosan, titanium dioxide and
the nanoassemblies are shown in Fig. 2. This ﬁgure shows a single
broad UV absorption peak at 259 nm for TiO2, while no absorption
peak for glucantime, chitosan and glucantime-chitosan NPs. Sim-
ilar to TiO2, glucantime-chitosan-TiO2 nanoassemblies displayed
a relatively high UV−vis absorbance in the same wavelength, and
the shift of the characteristic peak from 252 nm in TiO2 to 259 nm
in nanoassemblies suggests conjugation of TiO2 to glucantime-
chitosan NPs.
The results of physicochemical properties of different formula-
tions of nanoassemblies are shown in Table 2. The particle size and
the PDI of different formulations was between 170.56–853.43 nm
and 0.19–0.55, respectively.
Analysis of the results of Table 2 by Deign Expert Software
showed a linear model was best ﬁtted to the results of particle
size and a quadratic model to zeta potential of nanoassemblies
(P < 0.05). The concentrations of chitosan and TiO2 had signiﬁcant
effect on particle size (P < 0.0001) so that, by increasing the amount
of both these variables the particle size of nanoassemblies increased
(Table 2). All the studied variables had also signiﬁcant effects on the
zeta potential of nanoassemblies (P < 0.05).
3.2. Determination of antimony loaded in nanoassemblies of TiO2
NPs and chitosan-glucantime
ICP-OES analysis at wavelength of 217.582 nm was used
for determining of antimony in the prepared nanoassemblies.
The concentration of antimony in the optimum formulation of
nanoassemblies (G12.5C25T6) was 68.22%. The results of Table 2
showed the loading efﬁciency of formulations were between 67 and
78%. The best model ﬁtted to the results of the loading efﬁciency
was a quadratic model (P < 0.05). The concentration of glucantime
had a signiﬁcant increasing effect on the loading efﬁcacy (P < 0.05).
However, the effects of chitosan and TiO2 concentrations was not
signiﬁcant on the loading efﬁcacy (P > 0.05) (Table 2).
3.3. In vitro release of glucantime from nanoa ssemblies of TiO2
NPs and chitosan-glucantime
The release proﬁle of antimony versus time was measured by
ICP-OES analysis in the wavelength of 217.582 nm for the prepared
nanoassemblies in 11 formulations (Fig. 3). In the optimum for-
mulation (G12.5C25T6) 82.73% of the loaded antimony was released
within 24 h. The results of Table 2 show the release efﬁciency
of the drug over 24 h for different formulations. Analysis of data
showed that the concentration of components of nanoassenblies
did not have signiﬁcant effect on the release efﬁciency of glucan-
time (P > 0.05).
216 J. Varshosaz et al. / International Journal of Biological Macromolecules 107 (2018) 212–221
Fig. 2. UV–vis spectrum of glucantime, chitosan, glucantime-chitosan, titanium dioxide and the nanoassemblies.
Table 2
Particle size, zeta potential, loading efﬁciency and release efﬁciency of glucantime over 24 h (RE24%) from nanoassemblies of TiO2 NPs and glucantime.
PdI ± SD RE24% ± SD Drug release% over 24 h Loading efﬁciency% ± SD Zeta potential (mV) ± SD Mean particle size (nm) ± SD Formulation code
0.41 ± 0.02 44.8 ± 9.8 45.6 70.4 ± 1.5 +71.4 ± 5.3 400.8 ± 43.3 G18.75C37.5T4.65
0.38 ± 0.05 63.0 ± 10.0 82.7 68.2 ± 1.6 +42.8 ± 8.7 170.6 ± 22.7 G12.5C25T6
0.34 ± 0.03 37.4 ± 3.4 31.2 76.3 ± 0.8 +64.2 ± 7.44 365.8 ± 53.0 G18.75C19.82T9.25
0.42 ± 0.07 33.5 ± 10.0 41.3 73.3 ± 1.1 +78.1 ± 2.27 649.6 ± 15.1 G12.5C50T12.5
0.38 ± 0.00 49.5 ± 3.7 65.1 76.2 ± 1.8 +72.6 ± 2.30 522.4 ± 6.2 G18.75C37.5T9.25
0.37 ± 0.04 47.3 ± 13.0 42.3 73.2 ± 0.7 +70.8 ± 3.0 365.0 ± 10.9 G25C50T6
0.44 ± 0.06 55.2 ± 10.0 53.6 73.5 ± 0.8 +77.9 ± 2.1 853.4 ± 64.5 G18.75C37.5T13.85
0.24 ± 0.17 69.9 ± 10.0 74.6 77.1 ± 2.0 +70.3 ± 1.5 578.6 ± 51.9 G27.59C37.5T9.25
0.37 ± 0.06 41.3 ± 20.0 40.0 73.5 ± 1.0 +71.2 ± 0.4 753.0 ± 28.6 G18.75C55.18T9.25
0.55 ± 0.16 94.0 ± 8.0 100.0 77.7 ± 0.9 +74.5 ± 0.6 662.1 ± 51.1 G25C25T12.5
0.19 ± 0.08 75.2 ± 1.1 75. 9 67.2 ± 2.0 +57.3 ± 1.6 509.3 ± 21.4 G9.91C37.5T9.25
t form
3
E
oFig. 3. Release proﬁles of differen
.4. Optimization of the formulation of nanoassembliesComputer optimization process was performed using Design
xpert software and a desirability function determined the effect
f the levels of independent parameters on the responses.ulations of the nanoassemblies.
Table 2 displays that the constraint of particle size was
170.6 ± 22.7 nm ≤ Y1 ≤ 853.4 ± 64.5 nm with the goal set on mini-
mum.  For zeta potential it was  42.8 ± 8.7 mV  ≤ Y2 ≤ 78.1 ± 2.27 mV
and it was  set at the range of the data, for drug loading efﬁciency
the constraint was 68.2 ± 1.6% ≤ Y3 ≤ 77.7 ± 0.9% with targeting this
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tig. 4. A) TEM image of chitosan loaded NPs and B) the FE-SEM micrograph of
anoassemblies of chitosan-glucantime-TiO2.
ariable in the range of the data and the RE24% constraint was
3.5 ± 10.0% ≤ Y4 ≤ 94.0 ± 8.0% with the target set on maximum.
ptimization was performed and the optimized formulation was
uggested by desirability of 95%. The suggested formulation was
12.5C25T6, which was prepared with 12.5 mg  of glucantim, 25 mg
f chitosan and 6 mg  of TiO2 NPs.
.5. Morphology of chitosan-glucanthime NPs and
anoassemblies of chitosan-glucantime-TiO2 NPs
Fig. 4 shows the TEM image of chitosan-glucantime NPs and
he FE-SEM micrograph of nanoassemblies of chitosan-glucantime-
iO2. This ﬁgure indicates the chitosan nanoparticles loaded with
lucantime have spherical shapes with particle sizes less than
0 nm and when they are electrostatically conjugated to TiO2 NPs
he morphology changed to square, angled form.
.6. Cytotoxic effect of free glucantime, TiO2 NPs and
anoassemblies on L. major promastigotes
Analysis of the results of the growth of promastigotes in three
ime intervals and in the presence of different concentrations of
ree glucantime, TiO2 NPs and nanoassemblies showed that the
ime of exposure and also the concentration of different studied
roups had signiﬁcant effect on the proliferation of promastigotes
Fig. 5). All concentrations of the studied groups showed signiﬁcant
ifference with negative control group (P < 0.05). It was obvious
hat all different concentrations of nanoassemblies showed sig-ical Macromolecules 107 (2018) 212–221 217
niﬁcantly more anti-proliferative effect in comparison with free
glucantime (p < 0.05). Their highest suppressive effect was seen at
the concentration of 50 g/mL according to the pure content of
glucantime after 24 h which was 358,000 for free glucantime and
10,000 for nanoassemblies compared with 1,100,000 in negative
control group. However, none of the concentrations of TiO2 NPs had
considerable impact on promastigotes proliferation in comparison
with free glucantime (P < 0.05). Compared to the negative control
group TiO2 NPs were signiﬁcantly more effective in reduction of
the number of promastigots at all times of exposure and all studied
concentrations (p < 0.05) (Fig. 5).
3.7. Cytotoxic effect of free glucantime, TiO2 NPs and
nanoassemblies on L. major amastigotes
Results of Fig. 6 indicate that different studied time intervals of
exposure and different concentrations of each group had signiﬁcant
effects on the amastigotes proliferation (p < 0.05). All the studied
groups, including nanoassemblies, TiO2 NPs and free glucantime
had signiﬁcant difference with negative control group (p < 0.05).
The best suppressive effect of nanoassemblies on parasites was at
the concentration of 166.5 g/mL (containing 50 g/mL of free glu-
cantime) after 72 h which was signiﬁcantly better than the same
concentration of free glucantime (p < 0.05). Also the concentration
of 83.25 g/mL of nanoassemblies (containing 25 g/mL of free
glucantime) had a better anti-proliferative effect in comparison
with the same concentration of the free drug (p < 0.05). Although
the different concentrations of TiO2 NPs reduced the number of
amastigotes counting compared with negative control group sig-
niﬁcantly (p < 0.05), but a signiﬁcant decrease in the number of
amastigotes counting was not seen in comparison with free glu-
cantime as the positive control group (p > 0.05) (Fig. 6).
Fig. 7 represents visible light microscopy images of infected
macrophage cells with amastigotes after incubation with
nanoassemblies, TiO2 NPs and glucantime in the concentra-
tion of 50 g/mL in three different times exposure of 24, 48 and
72 h. As this ﬁgure indicates at 72 h although in the groups of free
glucantime and TiO2 NPs the number of amastigotes has reduced
compared to the negative control group, but the nanoassemblies
have destroyed the infected macrophages completely so that their
elongated shape and their false feet has diminished completely.
4. Discussion
Metal nanoparticle ions have cytotoxic effects as the Leish-
manicidal agents due to their activities on oxidative stress which
destroys parasites [7]. Also meglumine antimoniate (glucantime)
despite of all its problems and side effects is still the ﬁrst and
gold standard of treatment of Leishmaniasis [27]. Therefore, many
researches have been done to improve its efﬁcacy and decrease its
side effects and drug resistance. In the current study nanoassem-
blies of glucantime-chitosan and TiO2 NPs were prepared by
electrostatic interactions with loading efﬁciency of about 70% and
drug release of 83% over a 24 h period. To conﬁrm the electrostatic
interaction between the TiO2 NPs and chitosan, the UV spectrum of
different ingredients of the nanoassemblies were compared with
the conjugate (Fig. 2). TiO2 is widely used in sunscreen products
and often in combination with chemical UV-ﬁlters. Two  crystalline
forms, anatase and rutile, are available in different particle sizes,
with particles under 100 nm classiﬁed as nanoparticles, and the
larger particles as microparticles. Each particle size has a different
wavelength in UV range. Therefore, we used the same proper-
ties of TiO2 NPs to prove their binding to chitosan. The change
in the UV absorption peak of TiO2 NPs from 252 nm to 259 nm
in the nanoassemblies of chitosan-glucantime-TiO2 NPs conﬁrms
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he electrostatic conjugation of these NPs (Fig. 2). In a study con-
ucted by Venkatasubbu et al. [28] paclitaxel, an anticancer drug,
as attached to functionalized hydroxyapatite and titanium diox-
de nanoparticles and then the conjugates were characterized with
heir UV spectroscopy to conﬁrm the successful attachment of the
rug to NPs.Low molecular weight chitosan that is a water-soluble cationic
olymer was used as a biological macromolecule intermediate.
his polymer has been studied widely and has been consideredblies, TiO2 NPs and glucantime in the three different times exposure of A) 24 h, B)
biocompatible and biodegradable with a good stability [29]. The
presence of multiple amino functional groups in the backbone of
this polymer enhances the electrostatic entrapment of glucantime
in chitosan NPs through the interaction of the positive zeta poten-
tial of chitosan with the negative charge of the glucantime. The
results showed that the zeta potential of chitosan changed from
+70 mV  to +61 mV  when conjugated to the glucantime which shows
neutralization of some parts of the positive charge of chitosan
with negative glucantime. At last attachment of TiO2 NPs with
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eta potential of −59.4 mV  changed this positive surface charge
rom +61 mV  to +48 mV which conﬁrmed the production of self-
ssemblies via electrostatic forces. In a similar study in which the
nti-tumor drug of doxorubicin was electrostatically conjugated
o TiO2 NPs to use their synergistic anticancer effects, the surface
harge of TiO2 NPs changed from −26 mV  to −5 mV due to the
ositive NH2 functional group of doxorubicin [1,10].
TiO2 NPs were used to produce a synergistic effect with glu-
antime by producing reactive oxygen species that improves
he activity of macrophages and facilitates the efﬁcacy of glu-ssemblies, TiO2 NPs and glucantime in the three different times exposure of A) 24 h,
cantime effects on parasites. Beheshti et al. [30] studied the
efﬁcacy of selenium NPs against Leishmania major.  Their results
showed signiﬁcant reduction in the number of promastigotes in
present of selenium NPs. Also the cytotoxic studies on the infected
macrophages showed a dose-dependent response and highlighted
IC50 for the selenium NPs at the concentration of 10.5 ± 0.6 g/mL.
Allahverdiy et al. [31] studied the effect of silver (Ag) NPs under
ultraviolet (UV) light on the Leishmania tropica. The metabolic activ-
ity of parasite decreased with the increase of concentration of Ag
NPs [31]. A similar study was  conducted with these NPs combined
220 J. Varshosaz et al. / International Journal of Biological Macromolecules 107 (2018) 212–221
F tes aft
o
w
m
L
s
n
l
a
l
a
D
m
p
p
i
ﬂ
t
L
c
t
t
h
b
m
p
a
g
t
w
T
o
c
o
(
b
Aig. 7. Visible light microscopy images of infected macrophage cells with amastigo
f  50 g/mL in the three different times exposure of 24, 48 and 72 h.
ith the effect of UV radiation on animal models [32]. The antileish-
aniasis effect of ZnO NPs on the amastigote and promastigotes of
eishmania major has been also shown [33]. Torabi et al. [34] have
tudied on gold NPs and showed these NPs possessed antileishma-
ia activity on Leishmania major.
When the infected female Sandﬂy bites the human body, the
ife cycle of the leishmania parasite begins. Promastigots which
re extracellular ﬂagellated and animated spiny ﬁgure bodies with
ength of 20–25 m and width of 3–2 m are swallowed within
 few minutes by phagocytes, ie, macrophages and neutrophils.
ue to the short life span of neutrophils, macrophages are the
ain host of the leishmania parasite, where they multiply. After
romastigotes are swallowed by macrophages, they enter the
hagolysosomes, where they begin to differentiate and become
mmobilized small amastigotes with length of 2–4 m and without
agellum. Amastigotes rapidly proliferate and cause macrophage
earing and contamination of macrophages around them. Although
eishmania parasites in the infected host interact with a variety of
ell types, it could be said that macrophages and dendritic cells are
he most important cells that control the infection outcome [35].
The designed nanoassemblies of glucantime-chitosan-TiO2 in
he current study were exposed to the J774 cell line that acts like
uman macrophages in a condition most similar to the human
ody and their antileishmanial effects on amastigotes of Leish-
ania major was shown (Figs. 6 and 7). The increased drug
enetration into the macrophage cells was conﬁrmed by enhanced
nti-proliferative effects on amastigotes compared with the free
lucantime (Fig. 6). Although the number of promastigotes in nega-
ive control group increased over times of the study but this process
as slowed done in the group exposed to the nanoassemblies.
All studied groups including the designed nanoassemblies,
iO2 NPs and free glucantime signiﬁcantly inhibited the growth
f amastigotes and promastigotes in comparison with negative
ontrol group (p < 0.05) (Figs. 5 and 6). The equal concentration
f nanoassemblies of drug compared with the free glucantime
50 g/mL) showed obviously more effectiveness of nanoassem-
lies on reduction of the amastigotes count (p < 0.05) (Figs. 6 and 7).
lthough titanium dioxide was more effective than negative con-er incubation with nanoassemblies, TiO2 NPs and glucantime in the concentration
trol in reduction of amastigotes but it didn’t show signiﬁcant
difference compared with free glucantime (p > 0.05) (Fig. 6). This
shows that nanoassemblies of drug have more effectiveness than
each free glucantime or TiO2 NPs alone.
Abamor et al. study [26] who used the combinations of meg-
lumine antımoniate-TiO2@Ag nanoparticles demonstrated that
combination applications decreased the proliferation of L. top-
ica promastigotes 2- to 5-fold in contrast to use of meglumine
antımoniate alone. The results of Figs. 5 C and 6 C shows by incorpo-
rating of glucantime and TiO2 in a biomacromolecule like chitosan
at the concentration of 50 g/mL and after 72 h exposure the pro-
liferation of L. major promastigotes and amastigotes decreased 13
and 4-fold, respectively compared with glucantime alone.
5. Conclusions
The optimized nanoassemblies of glucantime-chitosan-
titanium dioxide prepared by electrostatic surface charge
interactions showed particle size of 170.6 ± 22.7 nm,  polydis-
persity index of 0.38 ± 0.05 and zeta potential of +42.8 ± 8.7 mV.
These nanoassemblies with 68.2 ± 1.6% drug loading efﬁciency
released 82.7% of the loaded drug over 24 h. The in vitro antileish-
manial effect of these nanoassembleis indicated that they were
much more effective than free glucantime and/or titanium dioxide
alone in reduction of promastigots and amastigots.
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